Savilahti Emma M, Kukkonen Anna K, Kuitunen Mikael, Savilahti Erkki
The Children's Hospital, University of Helsinki, Helsinki, Finland.
The Skin and Allergy Hospital, University of Helsinki, Helsinki, Finland.
Innate Immun. 2015 Apr;21(3):332-7. doi: 10.1177/1753425914541560. Epub 2014 Nov 27.
As innate immunity factors in breast milk (BM) modulate infants' immune responses, we investigated whether soluble CD14 (sCD14) and defensin levels in BM are associated with the emergence of allergy in childhood. The randomly selected group of 260 mother-child pairs belonged to a randomized, double-blind placebo-controlled trial where 1223 mothers with fetuses at high risk for allergy received for the 4 last wk of pregnancy a mixture of probiotics, or placebo; after birth, the child received the treatment for 6 mo. Children were followed for the emergence of sensitization and allergic symptoms for 5 yr. IgE-mediated allergic disorder was diagnosed in 80 children by the age of 5 yr. Levels of sCD14, human neutrophil peptide (HNP) 1-3 and β-defensin 2 (HBD2) in colostrum and in BM 3 mo post-partum were measured with ELISA. BM sCD14 levels decreased from 0 to 3 mo. HNP1-3 and HBD2 were detected in colostrum, but not in BM 3 mo post-partum. High sCD14 levels in BM 3 mo post-partum were associated with children developing an IgE-mediated allergic disorder by the age of 5 yr. BM HNP1-3, HBD2 or sCD14 levels were not associated with probiotics treatment. Our results suggest that sCD14 in BM influences the emergence of allergy in children with atopic heredity.
由于母乳中的固有免疫因子可调节婴儿的免疫反应,我们研究了母乳中可溶性CD14(sCD14)和防御素水平是否与儿童期过敏的发生有关。随机选取的260对母婴属于一项随机、双盲、安慰剂对照试验,其中1223名胎儿有过敏高风险的母亲在妊娠最后4周接受了益生菌混合物或安慰剂;出生后,婴儿接受该治疗6个月。对儿童进行了5年的致敏和过敏症状出现情况的随访。到5岁时,80名儿童被诊断为IgE介导的过敏性疾病。采用酶联免疫吸附测定法(ELISA)测量初乳和产后3个月母乳中sCD14、人中性粒细胞肽(HNP)1-3和β-防御素2(HBD2)的水平。母乳中sCD14水平从0个月降至3个月。初乳中检测到HNP1-3和HBD2,但产后3个月的母乳中未检测到。产后3个月母乳中sCD14水平高与5岁时发生IgE介导的过敏性疾病的儿童有关。母乳中HNP1-3、HBD2或sCD14水平与益生菌治疗无关。我们的结果表明,母乳中的sCD14会影响具有特应性遗传的儿童过敏的发生。